. The main route of infection is the inhalation of fungal particles, which usually leads to an asymptomatic infection 4 . There are two main clinical forms of PCM, acute/subacute and chronic. The acute/subacute form is characterized by a rapid disease course (weeks to months), impaired cellular immunity, an absence of delayed-type hypersensitivity reactions and a high mortality rate. The chronic form affects mainly 30-50 years old males with disease manifestations that are predominant pulmonary and/ or mucocutaneous 13 . In terms of mortality, based on data obtained from the Brazilian Ministry of Health´s Mortality Information, approximately 1,853 (~51,2%) of 3,583 confirmed deaths in Brazil due to systemic mycoses from 1996-2006 were caused by PCM 22 .
Expanding on the description of P. brasiliensis by Adolpho Lutz, modern molecular studies analyzing the genetic variability of strains revealed the existence of three distinct phylogenetic groups, namely: S1 -paraphyletic group with isolates from Argentina, Brazil, Peru and Venezuela; PS2 -monophyletic group with isolates from Brazil and Venezuela; and PS3 -monophyletic group with Colombian isolates only 30 . Subsequently, a complementary comparative genomic study identified an isolate that was separated from the other groups distributed on the Paracoccidioides cladogram 8 . This analysis led to a re-classification of this isolate as a new species within the genus, named Paracoccidioides lutzii 29 , which is now known to be endemic in the North and CentralWest regions of Brazil (States of Rondonia, Mato Grosso and Goias) and geographically partially overlaps with group S1. Despite the genetic differences, the pathogenesis and disease manifestations of P. brasiliensis and P. lutzii are indistinguishable at present. One important difference, is that P. lutzii does not properly express a key glycoprotein, gp43 30 , which is a target of vaccine development detailed below.
Antifungal chemotherapy is required for clinical PCM, although there is no certainty of total elimination of the fungus at the end of treatment. Initial treatment lasts from two to six months based on the extent of disease and clinical response to therapy, and typically includes the use of sulfa derivatives (sulfadiazine, sulfadoxine, sulfamethoxypyridazine, cotrimazine and trimethoprim-sulfamethoxazole) although amphotericin B, azoles (ketoconazole, itraconazole, fluconazole, voriconazole and posaconazole) or terbinafine may also be used. After the initial intensive therapy, extended periods of treatment are often necessary, up to two or more years, with a significant frequency of relapsing disease 3, 26 . 
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Protection against PCM has been attributed to the induction of cellular immune responses whereas high levels of specific antibodies have been associated with the symptomatic form of the disease. A major line of investigation has focused on purified antigens in the attempt to develop a peptide vaccine. The glycoprotein gp43 is the main antigen target of P. brasiliensis and a 15-mer internal peptide (QTLIAIHTLAIRYAN), known as P10, contains the major CD4 + specific T cell epitope and elicits an IFN-γ-dependent Th1 immune response. Immunization with P10 of intratracheally infected BALB/c mice, in the presence of complete Freund adjuvant (CFA) reduces the fungal burden in the lungs, liver and spleen 28, 32 .
The protection by P10 administered in CFA 18 observed in a prophylactic protocol was also obtained therapeutically in P. brasiliensisinfected immunocompetent mice. Similar results were observed in partially immunosuppressed mice 21 , in which case fibrosis was also precluded.
Complete Freund adjuvant causes a variety of side effects such as localized injection-site granulomas, hepatic and renal granuloma formation and necrotizing dermatitis. Hence, the use of this adjuvant has been banned in humans as well as in non-experimental veterinary administration 27 . With this in mind, our group tested the therapeutic effects of P10 combined with different adjuvants (aluminum hydroxide, CFA, flagellin and the cationic lipid dioctadecyl-dimethylammonium bromide (DODAB)) in BALB/c mice previously infected with P. brasiliensis 19 . Seventy days after infection, mice treated with DODAB and P10, and with less intensity, mice treated with P10 and flagellin, showed the most prominent effects. Concomitantly, secretion of IFN-γ and TNF-α, in contrast to IL-4 and IL-10, was enhanced in the lungs of mice immunized with P10 in combination with the tested adjuvants, with the best results observed in mice treated with P10 and DODAB
19
.
The incorportion of P10 in Poly (lactic acid-glycolic acid) nanoparticles (PLGA) at 1 μg/50μL with TMP/SMZ was also tested. It reduced the amount of peptide necessary to decrease the fungal load in the infected animals and avoid disease relapse when compared with P10 emulsified in Freund's adjuvant (20 μg/50μL) 2 .
The use of pcDNA3 expression vector encoding P10 was a gene therapy approach tested in intratracheally infected mice. The plasmid vaccine induced a significant reduction of fungal burden in the lung. Covaccination with a plasmid encoding mouse IL-12 proved to be even more effective in the elimination of the fungus with virtual sterilization in a long term (five months) infection and treatment assay 25 . The immunization with plasmid encoding P10 was also able to induce memory cells 6 .
Dendritic cells (DCs) pulsed with P10 protected mice infected with P. brasiliensis. The adoptive transference of pulsed dendritic cells in mice previously infected with the fungus reduced the fungal burden in their lungs 17 . FERREIRA et al., (2011) 12 used DCs transfected with plasmid (pMAC/PS-scFv) encoding a single chain variable fragment (scFv) of an anti-Id antibody that was capable of mimicking gp43. Mice immunized subcutaneously with pMAC/PS-scFv decreased the lung infection.
Other peptides from 43 kDa glycoprotein showed different properties such as P4 and P23 that inhibit macrophage functions and the inflammatory reaction, thus facilitating infection 14, 15 . P4 and P23 were evaluated in different models in vivo, and suggested that this anti-inflammatory effect depended on the kinetics of innate immunity modulators such as TNF-α, IL6, IL10 and TLR2. IL10 seems to be produced earlier than TNF-α and IL6, in presence of the peptides. The anti-inflammatory effects of P4 and P23 depended on the amount and frequency of treatment 15 .
Besides the use of gp43 and P10 as vaccines, other antigens have been investigated as additional vaccine options against P. brasiliensis. cDNA encoding the 27 kDa protein present at the surface and cytosol of P. brasiliensis was subcloned into a pET-DEST 42 plasmid and expressed in Escherichia coli (rPb27). BALB/c mice were infected with virulent P. brasiliensis and after being immunized subcutaneously with purified rPb27 in the presence of Corynebacterium parvum and aluminum hydroxide, some mice were also treated with fluconazol. After 40 days of treatment, the combined administration of plasmid and chemotherapeutics controlled PCM in the lung, liver and spleen 10, 11 . A therapeutic study was conducted to evaluate fibrosis development in animals immunized with rPb27 and infected. After 30 and 90 days postinfection reduced levels of collagen and receptor CCR7 were observed with high levels of active caspase 3, IFN-γ, TGF-β and IL-10 on the early phase of infection. In the control groups that developed high levels of pulmonary fibrosis, the molecule could be promising as a prophylactic and therapeutic treatment against PCM 20 . The use of rPb40 together with rPb27, combined with conventional treatment, exhibited additive protective effect 10 .
Recombinant paracoccin (the sequence matched a hypothetical protein encoded by PADG-3347 of P. brasiliensis 18, with a polypeptide sequence similar to endochitinase) expressed in E. coli cells showed protective effect in infected mice reducing the fungal burden 1 . Otherwise, radioattenuated yeast cells of P. brasiliensis reduced the fungal burden in infected mice 9 . DNAhsp65 (Heat shock protein from Mycobacterium leprae) administered by intramuscular immunization in BALB/c mice promoted an increase in Th-1 cytokines and reduced the fungal burden 24 .
The role of antibody-mediated immunity in PCM has been less certain as in early studies it was believed that antibodies were useful only for serological diagnosis. More recently, monoclonal antibodies (mAbs) have been shown to significantly modify PCM. The first demonstration of this utilized mAbs against gp70 of P. brasiliensis 7 . In fact, both protective and non-protective mAb have been identified as exemplified by a panel of mAbs recognizing gp43, of which mAb 3E was the most efficient in reducing the fungal burden in vivo and promoting fungal phagocytosis in vitro 5 . MAb 3E recognized the epitope sequence NHVRIPIGYWAV. Significantly, combining P10 preimmunization with the administered of mAb 3E 24 h before intratracheal challenge with virulent P. brasiliensis yeasts resulted in additive protection using a short-term protocol in comparison with a non-protective mAb 32 .
The mechanisms for protection against P. lutzii are not well elucidated. We recently demonstrated that mAbs generated against the heat shock protein 60 (Hsp60) from Histoplasma capsulatum interacted with P. lutzii yeast cells and enhanced phagocytosis by macrophages cells 31 . The passive transfer of Hsp60-binding mAbs 7B6 and 4E12 significantly reduced the lung fungal burden in BALB/c mice intratracheally infected with P. lutzii. 
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Although we currently have several therapeutic options for the treatment of PCM, these regimens require protracted administration of antifungal drugs, increasing both the costs of therapy and the incidence of toxicities. Moreover, there are frequent relapses despite more than one or two years to antifungal treatment. In light of this, efforts are underway to harness the host immune system to generate protective responses that can improve the efficacy and reduce the duration of treatment. The use of peptides, purified antigens, DNA therapy, peptide-pulsed DCs, radio attenuated yeast cells, monoclonal antibodies, etc. are being explored as potential components of a therapeutic vaccine. To date, these promising studies have provided results in experimental model or in vitro in patients' cells. We are now poised to transition the large amount of knowledge gained through these studies into clinical trials aimed at improving our ability to combat PCM.
RESUMO

Paracoccidioidomicose: desafios no desenvolvimento de uma vacina contra micose endêmica nas Américas
A paracoccidioidomicose (PCM), causada por Paracoccidioides spp, é importante micose endêmica na América Latina. Com base em diferenças filogenéticas, existem duas espécies reconhecidas de Paracoccidioides, P. brasiliensis e P. lutzii, no entanto, a patogênese e as manifestações clínicas de ambas são indistinguíveis atualmente. Aproximadamente 1853 (~51,2%) de 3583 mortes confirmadas, atribuídas a micoses sistêmicas de 1996-2006, no Brasil foram causadas por PCM. Tratamento antifúngico é necessário para pacientes com PCM. O tratamento inicial dura de dois a seis meses e derivados de sulfa, anfotericina B, azóis e terbinafina são utilizados na prática clínica; no entanto, apesar da terapêutica prolongada, as recaídas ainda são um problema. Uma resposta imune celular eficaz, tendendo a Th1, é essencial para controlar a doença que pode ser induzida por antígenos exógenos, ou moduladas por vacinas profiláticas ou terapêuticas. A estimulação de células B ou a transferência passiva de anticorpos monoclonais também são meios importantes que podem ser utilizados para melhorar a eficácia do tratamento da paracoccidioidomicose no futuro. Esta revisão detalha criticamente os principais desafios que o desenvolvimento de uma vacina para combater a PCM enfrenta.
